Trial · NCT03158285
Results by group2,681
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 2,681
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 | Placebo to Guselkumab 100 mg q4w | 32.9 | percentage of participants | ||
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 | Guselkumab 100 mg q8w | 64.1 | percentage of participants | ||
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 | Guselkumab 100 mg q4w | 63.7 | percentage of participants | ||
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24 | Placebo to Guselkumab 100 mg q4w | -0.1300 | 95% Confidence Interval -0.1912 to -0.0687 | units on a scale | |
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24 | Guselkumab 100 mg q8w | -0.3672 | 95% Confidence Interval -0.4282 to -0.3062 | units on a scale | |
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24 | Guselkumab 100 mg q4w | -0.4004 | 95% Confidence Interval -0.4617 to -0.3390 | units on a scale | |
| Percentage of Participants Who Achieved an ACR 50 Response at Week 24 | Placebo to Guselkumab 100 mg q4w | 14.2 | percentage of participants | ||
| Percentage of Participants Who Achieved an ACR 50 Response at Week 24 | Guselkumab 100 mg q8w | 31.5 | percentage of participants | ||
| Percentage of Participants Who Achieved an ACR 50 Response at Week 24 | Guselkumab 100 mg q4w | 33.1 | percentage of participants | ||
Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline | Placebo to Guselkumab 100 mg q4w | 19.1 | percentage of participants | ||
Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline | Guselkumab 100 mg q8w | 70.5 | percentage of participants | ||
Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline | Guselkumab 100 mg q4w | 68.5 | percentage of participants | ||
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16 | Placebo to Guselkumab 100 mg q4w | 33.7 | percentage of participants | ||
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16 | Guselkumab 100 mg q8w | 55.2 | percentage of participants | ||
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16 | Guselkumab 100 mg q4w | 55.9 | percentage of participants | ||
| Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24 | Placebo to Guselkumab 100 mg q4w | 0.95 | 95% Confidence Interval 0.61 to 1.29 | units on a scale | |
| Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24 | Guselkumab 100 mg q8w | 0.52 | 95% Confidence Interval 0.18 to 0.86 | units on a scale | |
| Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24 | Guselkumab 100 mg q4w | 0.29 | 95% Confidence Interval -0.05 to 0.63 | units on a scale | |
| Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline | Placebo to Guselkumab 100 mg q4w | 29.4 | percentage of participants | ||
| Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline | Guselkumab 100 mg q8w | 49.6 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03158285/results